메뉴 건너뛰기




Volumn 28, Issue 3 SUPPL. 59, 2010, Pages

Biologic agents in rheumatology: Act II

Author keywords

Certolizumab pegol; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

CORTICOSTEROID; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

EID: 77956411179     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial
Times cited : (1)

References (10)
  • 1
    • 36749030680 scopus 로고    scopus 로고
    • Tumor necrosis factor as a therapeutic target of rheumatologic disease
    • ACKERMANN C, KAVANAUGH A: Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007; 11: 1369-84.
    • (2007) Expert Opin Ther Targets , vol.11 , pp. 1369-1384
    • Ackermann, C.1    Kavanaugh, A.2
  • 2
    • 73349100044 scopus 로고    scopus 로고
    • Is rheumatoid arthritis really getting less severe?
    • UHLIG T, KVIEN TK: Is rheumatoid arthritis really getting less severe? Nat Rev Rheumatol 2009; 5: 461-4.
    • (2009) Nat Rev Rheumatol , vol.5 , pp. 461-464
    • Uhlig, T.1    Kvien, T.K.2
  • 3
    • 77956400778 scopus 로고    scopus 로고
    • Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis
    • FURST D: Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S5-S12.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.SUPPL. 59
    • Furst, D.1
  • 4
    • 77956415622 scopus 로고    scopus 로고
    • Impact of dosing on treatment with TNF inhibitors: Managing dose adjustment
    • COMBE B: Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S13-S17.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.SUPPL. 59
    • Combe, B.1
  • 5
    • 77956404181 scopus 로고    scopus 로고
    • The assessment of disease activity in rheumatoid arthritis
    • SMOLEN J, ALETAHA D: The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S18-S27.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.SUPPL. 59
    • Smolen, J.1    Aletaha, D.2
  • 6
    • 73349090959 scopus 로고    scopus 로고
    • Therapy: Guidelines in rheumatology: Quo vadis?
    • KAVANAUGH A: Therapy: Guidelines in rheumatology: Quo vadis? Nat Rev Rheum 2009; 5: 423-4.
    • (2009) Nat Rev Rheum , vol.5 , pp. 423-424
    • Kavanaugh, A.1
  • 7
    • 77956410442 scopus 로고    scopus 로고
    • The importance of the patients' experience of RA compared with clinical measures of disease activity
    • TAYLOR P: The importance of the patients' experience of RA compared with clinical measures of disease activity. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S28-S31.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.SUPPL. 59
    • Taylor, P.1
  • 8
    • 79955047169 scopus 로고    scopus 로고
    • The economics of rheumatoid arthritis management
    • SOLOMON DH, KAVANAUGH A: The economics of rheumatoid arthritis management. Int J Adv Rheumatol 2008; 6: 2-5.
    • (2008) Int J Adv Rheumatol , vol.6 , pp. 2-5
    • Solomon, D.H.1    Kavanaugh, A.2
  • 9
    • 77956404435 scopus 로고    scopus 로고
    • The impact of rheumatoid arthritis and treatment on patients' lives
    • STRAND V, KHANNA D: The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S32-S40.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.SUPPL. 59
    • Strand, V.1    Khanna, D.2
  • 10
    • 67649871980 scopus 로고    scopus 로고
    • Predicting the future of anti-tumor necrosis factor therapy
    • VERWEIJ C: Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res Therapy 2009; 11: 115.
    • (2009) Arthritis Res Therapy , vol.11 , pp. 115
    • Verweij, C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.